Arcutis Biotherapeutics (ARQT) Non-Current Assets (2019 - 2026)
Arcutis Biotherapeutics (ARQT) posted quarterly Non-Current Assets of $21.9 million for Q1 2026, up 7.4% year-over-year from $20.4 million in Q1 2025, and up 0.95% quarter-over-quarter from $21.7 million in Q4 2025.
Arcutis Biotherapeutics (ARQT) Non-Current Assets (2019 - 2026) Analysis & Trends
Arcutis Biotherapeutics' Non-Current Assets history runs 8 years deep, the most recent figure standing at $21.9 million for Q1 2026.
- In Q1 2026, Non-Current Assets rose 7.4% year-over-year to $21.9 million; the TTM figure through Mar 2026 stood at $85.1 million (up 48.5% YoY), while the FY2025 annual figure was $21.7 million, up 66.36% from the prior year.
- Non-Current Assets for Q1 2026 stood at $21.9 million, up from $21.7 million in the prior quarter.
- The five-year high for Non-Current Assets was $21.9 million in Q1 2026, with the low at $5.0 million in Q2 2022.
- The 5-year median for Non-Current Assets is $11.9 million (2022), against an average of $13.7 million.
- The sharpest annual moves came in 2023 and 2024: Non-Current Assets jumped 134.64% in 2023, then slipped 13.98% in 2024.
- Arcutis Biotherapeutics' Non-Current Assets stood at $11.9 million in 2022, then slipped by 7.87% to $10.9 million in 2023, then rose by 19.53% to $13.1 million in 2024, then jumped by 66.36% to $21.7 million in 2025, then grew by 0.95% to $21.9 million in 2026.
- Business Quant data shows ARQT's Non-Current Assets at $21.9 million in Q1 2026, $21.7 million in Q4 2025, and $21.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.96 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 294.93 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.96 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 18.06 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 938.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 468.65 Mn |
| 10 | Arcutis Biotherapeutics | 3.29 Bn | 3.05 Bn | 118.92 Mn | 20.87 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 20.87 Mn |
| Mar 31, 2026 | 21.95 Mn |
| Dec 31, 2025 | 21.74 Mn |
| Sep 30, 2025 | 21.75 Mn |
| Jun 30, 2025 | 19.66 Mn |
| Mar 31, 2025 | 20.43 Mn |
| Dec 31, 2024 | 13.07 Mn |
| Sep 30, 2024 | 13.63 Mn |
| Jun 30, 2024 | 10.17 Mn |
| Mar 31, 2024 | 10.48 Mn |
| Dec 31, 2023 | 10.93 Mn |
| Sep 30, 2023 | 11.41 Mn |
| Jun 30, 2023 | 11.82 Mn |
| Mar 31, 2023 | 11.78 Mn |
| Dec 31, 2022 | 11.87 Mn |
| Sep 30, 2022 | 12.20 Mn |
| Jun 30, 2022 | 5.04 Mn |
| Mar 31, 2022 | 5.19 Mn |
| Dec 31, 2021 | 5.38 Mn |
| Sep 30, 2021 | 5.24 Mn |